All Stories

  1. A three variant risk score with similar thrombotic risk as factor V Leiden
  2. Microscopic Colitis and Risk of Venous Thromboembolism: A Nationwide Matched Cohort Study
  3. Thrombotic risk determined by CREB3L1 variants in a population-based cohort study: linkage disequilibrium with prothrombin mutation
  4. Multimorbidity is associated with risk of incident venous thromboembolism – A nationwide proof-of-concept study
  5. Trends in mortality rate after cancer-related thrombosis give hope for the future
  6. Response to Comment on: Multimorbidity, comorbidity, frailty, and venous thromboembolism
  7. The risk for psychiatric disorders in offspring from thrombosis-prone pedigrees in Sweden: a nationwide family study
  8. Tissue factor (F3) gene variants and thrombotic risk among middle-aged and older adults: A population-based cohort study
  9. Multimorbidity, comorbidity, frailty, and venous thromboembolism
  10. miR-145 and incident thromboembolism
  11. Familial risk of vasospastic angina: a nationwide family study in Sweden
  12. Rare-variant collapsing and bioinformatic analyses for different types of cardiac arrhythmias in the UK Biobank reveal novel susceptibility loci and candidate amyloid-forming proteins
  13. Association between Hereditary Angioedema and Venous Thromboembolism in a Large Population-Based Case-Control Study
  14. Contribution of rare genetic variants to heart failure and cardiomyopathy in the UK Biobank
  15. Review of gene collapsing analysis for arterial and venous cardiovascular diseases
  16. The role of fibrinolysis in vascular diseases in UK biobank
  17. Lung function, respiratory symptoms and incident venous thromboembolism during a 44-year follow-up
  18. Bioinformatics Reveals Novel Diabetes Susceptibility Genes
  19. Multimorbidity can run in families—what are implications for clinical practice?
  20. Rare-variant collapsing and bioinformatic analyses for amyloidosis, dementia and Parkinson’s disease in the UK biobank reveal novel susceptibility loci
  21. Familial aggregation of multimorbidity in Sweden: national explorative family study
  22. A hypothesis - generating Swedish extended national cross-sectional family study of multimorbidity severity and venous thromboembolism
  23. Rare variation contributes to hypertension
  24. Sex‐Specific Risk Factors for Deep Venous Thrombosis and Pulmonary Embolism in a Population‐Based Historical Cohort Study of Middle‐Aged and Older Individuals
  25. Familial Associations of Complete Atrioventricular Block: A National Family Study in Sweden
  26. Contribution of rare and common coding variants to haematological malignancies in the UK biobank
  27. 1059 FAMILIAL RISK OF DILATED AND HYPERTROPHIC CARDIOMYOPATHY: A NATIONAL FAMILY STUDY IN SWEDEN
  28. Genetic variation of the blood coagulation regulator tissue factor pathway inhibitor and venous thromboembolism among middle‐aged and older adults: A population‐based cohort study
  29. Familial risk of dilated and hypertrophic cardiomyopathy: a national family study in Sweden
  30. Thrombotic risk determined by rare and common SERPINA1 variants in a population‐based cohort study
  31. Association between self-rated health and venous thromboembolism in Malmö Preventive Program: A cohort study
  32. Familial Mortality Risks in Patients With Ischemic Stroke: A Swedish Sibling Study
  33. Air pollution and biomarkers of cardiovascular disease and inflammation in the Malmö Diet and Cancer cohort
  34. Thrombomodulin (THBD) gene variants and thrombotic risk in a population‐based cohort study
  35. Classic Thrombophilias and Thrombotic Risk Among Middle‐Aged and Older Adults: A Population‐Based Cohort Study
  36. Thrombotic Risk Determined by Protein C Receptor (PROCR) Variants among Middle-Aged and Older Adults: A Population-Based Cohort Study
  37. Familial Segregation of Venous Thromboembolism in Sweden: A Nationwide Family Study of Heritability and Complex Segregation Analysis
  38. Thrombotic Risk Determined by STAB 2 Variants in a Population-Based Cohort Study
  39. Mitochondria-DNA copy-number and incident venous thromboembolism among middle-aged women: a population-based cohort study
  40. Risk Factors for Syncope Associated With Multigenerational Relatives With a History of Syncope
  41. Effect of mindfulness on physical activity in primary healthcare patients: a randomised controlled trial pilot study
  42. Reactome Pathway Analysis of Venous Thromboembolism, Peripheral Artery Disease, Stroke, and Coronary Artery Disease
  43. Neighborhood socioeconomic status and aortic stenosis: A Swedish study based on nationwide registries and an echocardiographic screening cohort
  44. Genetic risk factors for venous thromboembolism
  45. Mortality risks associated with sibling heart failure
  46. Risk of Stroke in Patients With Atrial Fibrillation Is Associated With Stroke in Siblings: A Nationwide Study
  47. Self-rated health and venous thromboembolism among middle-aged women: a population-based cohort study
  48. Genetics of venous thromboembolism revised
  49. J‐curve association between alcohol intake and varicose veins in Japan: The Shimane CoHRE Study
  50. Next-Generation Sequencing of 17 Genes Associated with Venous Thromboembolism Reveals a Deficit of Non-Synonymous Variants in Procoagulant Genes
  51. Heritability of glomerulonephritis: A Swedish adoption study
  52. Familial association of attention-deficit hyperactivity disorder with autoimmune diseases in the population of Sweden
  53. Outcomes associated with dual antiplatelet therapy after myocardial infarction in patients with aortic stenosis
  54. New functional test for theTFPIαcofactor activity of Protein S working in synergy withFV‐Short
  55. Association of Genetic vs Environmental Factors in Swedish Adoptees With Clinically Significant Tinnitus
  56. Association of recurrent venous thromboembolism and circulating microRNAs
  57. Cardiovascular Risk Factors Associated With Venous Thromboembolism
  58. Association of Short-Term Mortality of Venous Thromboembolism with Family History of Venous Thromboembolism and Charlson Comorbidity Index
  59. Familial Mortality Risks in Patients With Heart Failure—A Swedish Sibling Study
  60. Alpha 2-macroglobulin 5 bp insertion/deletion polymorphism increases the risk of recurrent venous thromboembolism
  61. Pilot study on increased adherence to physical activity on prescription (PAP) through mindfulness: study protocol
  62. Hospitalization rate of paroxysmal supraventricular tachycardia in Sweden
  63. Postoperative Joint Replacement Complications in Swedish Patients With a Family History of Venous Thromboembolism
  64. Characteristics and prognosis of healthy severe obesity (HSO) subjects - The Malmo Preventive Project
  65. Prevalence and in silico analysis of missense mutations in the PROS1 gene in the Swedish population: The SweGen dataset
  66. Dementia and Alzheimer's disease risks in patients with autoimmune disorders
  67. Heritability of heart failure estimated among Swedish adoptees
  68. Familial Risks of Glaucoma in the Population of Sweden
  69. Association of irritable bowel syndrome and venous thromboembolism
  70. Identification of novel diagnostic biomarkers for deep venous thrombosis
  71. Polymorphisms in PARK2 and MRPL37 are associated with higher risk of recurrent venous thromboembolism in a sex-specific manner
  72. Fat mass and obesity-associated gene rs9939609 polymorphism is a potential biomarker of recurrent venous thromboembolism in male but not in female patients
  73. Factor V Leiden paradox in a middle-aged Swedish population: A prospective study
  74. Family history of diabetes and its relationship with insulin secretion and insulin sensitivity in Iraqi immigrants and native Swedes: a population-based cohort study
  75. Familial Aggregation of Aortic Valvular StenosisCLINICAL PERSPECTIVE
  76. Perinatal and familial risk factors for irritable bowel syndrome in a Swedish national cohort
  77. Heritability of End-Stage Renal Disease: A Swedish Adoption Study
  78. A Swedish national adoption study of risk of irritable bowel syndrome (IBS)
  79. Heritability of Mitral RegurgitationCLINICAL PERSPECTIVE
  80. Evaluation of Expression Level of Apolipoprotein M as a Diagnostic Marker for Primary Venous Thromboembolism
  81. Body Height and Incident Risk of Venous ThromboembolismCLINICAL PERSPECTIVE
  82. Quantification of mitochondrial DNA copy number in suspected cancer patients by a well optimized ddPCR method
  83. Epidemiology of valvular heart disease in a Swedish nationwide hospital-based register study
  84. Association between TLR9 rs5743836 polymorphism and risk of recurrent venous thromboembolism
  85. Risk of ocular manifestations in patients with giant cell arteritis: a nationwide study in Sweden
  86. Seasonal variation of pulmonary embolism and age dependence
  87. Risk of pulmonary embolism and deep venous thrombosis in patients with asthma: a nationwide case−control study from Sweden
  88. Identification of Genetic Aberrations in Thrombomodulin Gene in Patients With Recurrent Venous Thromboembolism
  89. A sibling based design to quantify genetic and shared environmental effects of venous thromboembolism in Sweden
  90. Family history of venous thromboembolism and mortality after venous thromboembolism: a Swedish population-based cohort study
  91. Cardiovascular fitness in young males and risk of unprovoked venous thromboembolism in adulthood
  92. Sibling risk of hospitalization for heart failure – A nationwide study
  93. Epidemiology of Familial Aggregation of Venous Thromboembolism
  94. Familial Transmission of Hospital-Treated Varicose Veins in Adoptees: A Swedish Family Study
  95. Venous thromboembolism and eye disease
  96. Identification of polymorphisms in Apolipoprotein M gene and their relationship with risk of recurrent venous thromboembolism
  97. Diagnostic potential of plasma microRNA signatures in patients with deep-vein thrombosis
  98. High Risk of Venous Thromboembolism in Klinefelter Syndrome
  99. Cognitive ability in Swedish conscripts and future risk of venous thromboembolism: A co-relative prospective national study
  100. Risk of solid tumors and hematological malignancy in persons with Turner and Klinefelter syndromes: A national cohort study
  101. Familial risks of glomerulonephritis – a nationwide family study in Sweden
  102. A nationwide family study of venous thromboembolism and risk of arterial vascular disease
  103. Thrombomodulin gene c.1418C>T polymorphism and risk of recurrent venous thromboembolism
  104. Role of family history of venous thromboembolism and thrombophilia as predictors of recurrence: a prospective follow-up study
  105. Family history of venous thromboembolism is a risk factor for venous thromboembolism in combined oral contraceptive users: a nationwide case-control study
  106. Risk of breast cancer among patients with bioprosthetic or mechanical valve replacement: a population-based study in Sweden
  107. Soluble urokinase plasminogen activator receptor and incidence of venous thromboembolism
  108. Genetic aspects of thrombotic disease
  109. Family history of venous thromboembolism and risk of hospitalized thromboembolism in cancer patients: A nationwide family study
  110. Family history of venous thromboembolism as a risk factor and genetic research tool
  111. Plasminogen activator inhibitor-1 4G/5G polymorphism, factor V Leiden, prothrombin mutations and the risk of VTE recurrence
  112. Perinatal risk factors for premature ischaemic heart disease in a Swedish national cohort
  113. Neighbourhood Deprivation, Individual-Level and Familial-Level Socio-demographic Factors and Risk of Congenital Heart Disease: A Nationwide Study from Sweden
  114. Familial transmission of chronic obstructive pulmonary disease in adoptees: a Swedish nationwide family study
  115. Impact of hypertension on the outcome of patients admitted with acute coronary syndrome
  116. Neighborhood Deprivation and Lung Cancer Incidence and Mortality: A Multilevel Analysis from Sweden
  117. Alcohol use disorders are associated with venous thromboembolism
  118. Familial Risks of Kidney Failure in Sweden: A Nationwide Family Study
  119. End stage renal disease risk and neighbourhood deprivation: A nationwide cohort study in Sweden
  120. The association between apolipoprotein M and insulin resistance varies with country of birth
  121. Circulating human epidermal growth factor receptor 2 (HER2) is associated with hyperglycaemia and insulin resistance循环中的人类表皮生长因子受体2(HER2)与高血糖以及胰岛素抵抗有关
  122. Familial transmission of prostate, breast and colorectal cancer in adoptees is related to cancer in biological but not in adoptive parents: A nationwide family study
  123. Venous Thromboembolism and Varicose Veins Share Familial Susceptibility: A Nationwide Family Study in Sweden
  124. Low degree of shared genetic susceptibility to coronary artery disease and venous thromboembolism
  125. Gestational Age and Risk of Venous Thromboembolism From Birth Through Young Adulthood
  126. Response to the Authors
  127. Neighborhood deprivation and childhood autism: A nationwide study from Sweden
  128. Familial Transmission of Venous Thromboembolism
  129. Risk of irritable bowel syndrome in first-degree, second-degree and thirddegree relatives of affected individuals: a nationwide family study in Sweden
  130. Apolipoprotein M and the risk of unprovoked recurrent venous thromboembolism
  131. Red cell distribution width and risk for venous thromboembolism: A population-based cohort study
  132. Family history of venous thromboembolism and risk of recurrent VTE
  133. Determination of 14 Circulating microRNAs in Swedes and Iraqis with and without Diabetes Mellitus Type 2
  134. Transforming growth factor (TGF)-β levels and unprovoked recurrent venous thromboembolism
  135. Neighborhood, family, and childhood and adolescent epilepsy: A nationwide epidemiological study from Sweden
  136. Neighbourhood Deprivation, Individual-Level Familial and Socio-Demographic Factors and Diagnosed Childhood Obesity: A Nationwide Multilevel Study from Sweden
  137. Nationwide Family Studies of Cardiovascular Diseases – Clinical and Genetic Implications of Family History
  138. Family history as a predictor of hospitalization for hypertension in Sweden
  139. Shared and non-shared familial susceptibility of coronary heart disease, ischemic stroke, peripheral artery disease and aortic disease
  140. Age-and sex-specific seasonal variation of venous thromboembolism in patients with and without family history: a nationwide family study in Sweden
  141. Low prevalence of irritable bowel syndrome in primary health care in four Swedish counties
  142. Shared and Nonshared Familial Susceptibility to Surgically Treated Inguinal Hernia, Femoral Hernia, Incisional Hernia, Epigastric Hernia, and Umbilical Hernia
  143. Occupational and socio-economic risk factors for giant cell arteritis: a nationwide study based on hospitalizations in Sweden
  144. Time trends in pulmonary embolism: A matter of age and gender
  145. Mothers, places and risk of hospitalization for childhood asthma: a nationwide study from Sweden
  146. Venous thromboembolism does not share strong familial susceptibility with pre‐eclampsia/eclampsia: a nationwide family study in Sweden
  147. Neighbourhood deprivation and hospitalization for atrial fibrillation in Sweden
  148. Familial risk of venous thromboembolism in first-, second- and third-degree relatives: a nationwide family study in Sweden
  149. Risk of hospitalization for type 2 diabetes in first- and second-generation immigrants in Sweden: a nationwide follow-up study
  150. Erratum to Zöller et al. "Familial risk of venous thromboembolism in first-, second- and third-degree relatives: a nationwide family study in Sweden"
  151. High Familial Risk of Atrial Fibrillation/Atrial Flutter in Multiplex Families: A Nationwide Family Study in Sweden
  152. Family history as a risk factor for recurrent hospitalization for lone atrial fibrillation: a nationwide family study in Sweden
  153. Neighborhood deprivation and risk of cervical cancer morbidity and mortality: A multilevel analysis from Sweden
  154. A nationwide family study of pulmonary embolism: Identification of high risk families with increased risk of hospitalized and fatal pulmonary embolism
  155. Risk of haemorrhagic and ischaemic stroke in patients with cancer: A nationwide follow-up study from Sweden
  156. Multiplex sibling history of coronary heart disease is a strong risk factor for coronary heart disease
  157. Risk of subsequent ischemic and hemorrhagic stroke in patients hospitalized for immune-mediated diseases: a nationwide follow-up study from Sweden
  158. Small and large PROS1 deletions but no other types of rearrangements detected in patients with protein S deficiency
  159. Family history and risk of hospital treatment for varicose veins in Sweden
  160. Socioeconomic and occupational risk factors for venous thromboembolism in Sweden: A nationwide epidemiological study
  161. Neighborhood deprivation and hospitalization for venous thromboembolism in Sweden
  162. Increased Risks of Coronary Heart Disease and Stroke Among Spousal Caregivers of Cancer Patients
  163. Risk of Subsequent Coronary Heart Disease in Patients Hospitalized for Immune-Mediated Diseases: A Nationwide Follow-Up Study from Sweden
  164. Occupational Risk Factors for Systemic Lupus Erythematosus: A Nationwide Study Based on Hospitalizations in Sweden
  165. Risk of venous thromboembolism in first- and second-generation immigrants in Sweden
  166. Risk of coronary heart disease in patients with cancer: A nationwide follow-up study from Sweden
  167. Risk of pulmonary embolism in patients with autoimmune disorders: a nationwide follow-up study from Sweden
  168. Shared familial aggregation of susceptibility to different manifestations of venous thromboembolism: a nationwide family study in Sweden
  169. Venous Thromboembolism Does Not Share Strong Familial Susceptibility With Ischemic Stroke
  170. Age- and Gender-Specific Familial Risks for Venous Thromboembolism
  171. Familial risk factors shared by venous thromboembolism and cancer: A nationwide epidemiological study of Swedish families
  172. Venous thromboembolism does not share strong familial susceptibility with coronary heart disease: a nationwide family study in Sweden
  173. Determination of age-specific and sex-specific familial risks for the different manifestations of venous thromboembolism: A nationwide family study in Sweden
  174. Parental history and venous thromboembolism: a nationwide study of age‐specific and sex‐specific familial risks in Sweden
  175. Familial risks of unusual forms of venous thrombosis: a nationwide epidemiological study in Sweden
  176. Large deletions of the PROS1 gene in a large fraction of mutationnegative patients with protein S deficiency
  177. Co‐segregation of the PROS1 locus and protein S deficiency in families having no detectable mutations in PROS1
  178. Naturally occurring mutations in the thrombomodulin gene leading to impaired expression and function
  179. Improved Hemoglobin Status and Reduced Menstrual Blood Loss among Female Carriers of Factor V Leiden – An Evolutionary Advantage?
  180. The Ala25-Thr Mutation in the Thrombomodulin Gene Is not Frequent in Swedish Patients Suffering from Ischemic Heart Disease
  181. Factor V Q506 (Resistance to Activated Protein C) and Prognosis after Acute Coronary Syndrome
  182. Clarification of the Risk for Venous Thrombosis Associated with Hereditary Protein S Deficiency by Investigation of a Large Kindred with a Characterized Gene Defect
  183. Resistance to activated protein C, the FV: Q506 allele, and venous thrombosis
  184. A New Direct, Fast and Quantitative Enzyme-linked Ligandsorbent Assay for Measurement of Free Protein S Antigen
  185. A Common 4G Allele in the Promoter of the Plasminogen Activator Inhibitor-1 (PAI-1) Gene as a Risk Factor for Pulmonary Embolism and Arterial Thrombosis in Hereditary Protein S Deficiency
  186. ACTIVATED PROTEIN C RESISTANCE CAUSED BY A COMMON FACTOR V MUTATION HAS A SINGLE ORIGIN.
  187. ACTIVATED PROTEIN C RESISTANCE DUE TO A COMMON FACTOR V GENE MUTATION IS A MAJOR RISK FACTOR FOR VENOUS THROMBOSIS
  188. The factor VR506Q mutation causing APC resistance is highly prevalent amongst unselected outpatients with clinically suspected deep venous thrombosis
  189. State-of-the-Art Review: Activated Protein C Resistance: Clinical Implications
  190. A Common Thrombomodulin Amino Acid Dimorphism Is Associated with Myocardial Infarction
  191. Evaluation of Original and Modified APC-Resistance Tests in Unselected Outpatients with Clinically Suspected Thrombosis and in Healthy Controls
  192. A Novel Thrombomodulin Gene Mutation in a Patient Suffering from Sagittal Sinus Thrombosis
  193. Factor V:Q506 mutation and anticardiolipin antibodies in systemic lupus erythematosus
  194. Activated protein C resistance as a basis for venous thrombosis
  195. Editorial
  196. Resistance to activated protein C, the FV : Q 506 allele, and venous thrombosis
  197. Prevalence of factor V gene mutation amongst myocardial infarction patients and healthy controls is higher in Sweden than in other countries
  198. Resistance to activated protein C due to a factor V gene mutation
  199. Familial thrombophilia: Clinical and molecular analysis of Swedish families with inherited resistance to activated protein C or protein S deficiency
  200. Familial thrombophilia: Clinical and molecular analysis of Swedish families with inherited resistance to activated protein C or protein S deficiency
  201. Inherited resistance to activated protein C and venous thrombosis
  202. Inherited Resistance To Activated Protein C Caused By Presence Of The FV:Q506 Allele As A Basis Of Venous Thrombosis
  203. Actuated protein C resistance: From phenotype to genotype and clinical practice
  204. Resistance to activated protein C caused by a Factor V gene mutation
  205. Methodological Considerations on the Determination of the APC Response in Plasma
  206. Identification of the same factor V gene mutation in 47 out of 50 thrombosis-prone families with inherited resistance to activated protein C.
  207. Myocardial infarction associated with homozygous resistance to activated protein C
  208. Linkage between inherited resistance to activated protein C and factor V gene mutation in venous thrombosis